NMRA Stock Overview
A clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Neumora Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.37 |
| 52 Week High | US$21.00 |
| 52 Week Low | US$1.83 |
| Beta | 0 |
| 1 Month Change | -77.15% |
| 3 Month Change | -84.61% |
| 1 Year Change | -84.81% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.42% |
Recent News & Updates
Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Jan 03Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck
Dec 24Recent updates
Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Jan 03Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck
Dec 24Neumora Therapeutics: A Story Of A Class II Biotech
Oct 16We're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely
Jun 18
Neumora: Phase 3 MDD Readout In H2-24 Could Get Ball Rolling
Feb 08Shareholder Returns
| NMRA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -77.6% | 0.7% | 0.7% |
| 1Y | -84.8% | 2.8% | 23.9% |
Return vs Industry: NMRA underperformed the US Pharmaceuticals industry which returned 2.8% over the past year.
Return vs Market: NMRA underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| NMRA volatility | |
|---|---|
| NMRA Average Weekly Movement | 25.9% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NMRA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NMRA's weekly volatility has increased from 15% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 109 | Henry Gosebruch | www.neumoratx.com |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders.
Neumora Therapeutics, Inc. Fundamentals Summary
| NMRA fundamental statistics | |
|---|---|
| Market cap | US$416.83m |
| Earnings (TTM) | -US$293.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs NMRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NMRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$293.70m |
| Earnings | -US$293.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.82 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NMRA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 22:53 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neumora Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Charlie Yang | BofA Global Research |
| Yatin Suneja | Guggenheim Securities, LLC |